The cancer-associated "R462Q" mutation results in a glutamine instead of an arginine at position 462 of the RNase L enzyme, reducing its catalytic activity.
The cancer-related "R462Q" mutation leads to a glutamine instead of an arginine at position 462 of the RNase L enzyme, decreasing its catalytic activity.